17 Hrs
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
17 Hrsالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
17 HrsReady to play
Ready to play
A clinical trial showed that the experimental malaria vaccine “PfSPZ-LARC2” achieved 87% efficacy: only two of the 15 people who received it became infected, compared with all seven participants who received a placebo, after being exposed to parasites 12 to 16 weeks after their final dose. The vaccine had a good safety profile and provided protection even though the parasite strain used in the trial differed from the strain used to develop it—a significant finding given the malaria parasite’s extensive genetic diversity.
Notice: This Is an AI-Generated Summary
Comments (0)